Google’s life sciences business gains $800 million funding in pivot to Asia

pharmafile | January 27, 2017 | News story | Medical Communications, Sales and Marketing China, Temasek, Verily, google 

Verily, a life sciences company owned by Alphabet, Google’s umbrella company, has announced that it has received $800 million in funding from Temasek. Verily requiring funding may seem an odd prospect, being part of the Alphabet group, but the investment comes more in the form of expertise rather than as strictly a capital investment.

Verily is turning its attention to the Asian market and Temasek is a Singapore-based investment company, with a good working knowledge of the Chinese market. Temasek has a portfolio of $180 billion, with the leading countries represented in that portfolio being China and Singapore. Temasek will receive a minority stake in the company and a seat on its operating board in exchange for the investment.

“Temasek has a history of thoughtful and enduring capital investments, including in life sciences and healthcare, and this commitment to a long-term collaboration with Verily is a meaningful affirmation of our strategy,” said Andrew Conrad, CEO of Verily. “With a substantial network and insights into the economies in Asia, Temasek will provide valuable guidance as we look to ex-US markets with our development partners.”

The latter part of the quote is the indication behind the interest in receiving financial backing from Temasek. Verily is currently working on numerous technology products to aid in healthcare, the most well-known example being its collaboration with Novartis on a smart-contact lens. The lens will measure the glucose levels of the wearer and thereby provide constant feedback to the user. The lens was slated for a 2016 release but this has been pushed back to sometime during 2017.

It is reported that Verily brings in sales of $10 million through licensing its technology.

Ben Hargreaves

Related Content

AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment

AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of …

AstraZeneca’s Forxiga approved in China for chronic heart failure treatment

AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk …

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic …

Latest content